358 related articles for article (PubMed ID: 28911925)
1. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial.
Harada T; Kosaka S; Elliesen J; Yasuda M; Ito M; Momoeda M
Fertil Steril; 2017 Nov; 108(5):798-805. PubMed ID: 28911925
[TBL] [Abstract][Full Text] [Related]
2. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Jensen JT; Garie SG; Trummer D; Elliesen J
Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.
Harada T; Momoeda M; Taketani Y; Hoshiai H; Terakawa N
Fertil Steril; 2008 Nov; 90(5):1583-8. PubMed ID: 18164001
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study.
Strowitzki T; Kirsch B; Elliesen J
J Fam Plann Reprod Health Care; 2012 Apr; 38(2):94-101. PubMed ID: 22454006
[TBL] [Abstract][Full Text] [Related]
5. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg.
Mabrouk M; Solfrini S; Frascà C; Del Forno S; Montanari G; Ferrini G; Paradisi R; Seracchioli R
Gynecol Endocrinol; 2012 Jun; 28(6):451-4. PubMed ID: 22132832
[TBL] [Abstract][Full Text] [Related]
6. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.
Klipping C; Duijkers I; Fortier MP; Marr J; Trummer D; Elliesen J
J Fam Plann Reprod Health Care; 2012 Apr; 38(2):73-83. PubMed ID: 22454003
[TBL] [Abstract][Full Text] [Related]
7. Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study.
Lang J; Yu Q; Zhang S; Li H; Gude K; von Ludwig C; Ren X; Dong L
J Womens Health (Larchmt); 2018 Feb; 27(2):148-155. PubMed ID: 29083258
[TBL] [Abstract][Full Text] [Related]
8. Potentized estrogen in homeopathic treatment of endometriosis-associated pelvic pain: A 24-week, randomized, double-blind, placebo-controlled study.
Teixeira MZ; Podgaec S; Baracat EC
Eur J Obstet Gynecol Reprod Biol; 2017 Apr; 211():48-55. PubMed ID: 28187404
[TBL] [Abstract][Full Text] [Related]
9. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
10. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.
Klipping C; Duijkers I; Fortier MP; Marr J; Trummer D; Elliesen J
J Fam Plann Reprod Health Care; 2012 Apr; 38(2):84-93. PubMed ID: 22454004
[TBL] [Abstract][Full Text] [Related]
11. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis.
Tanaka Y; Mori T; Ito F; Koshiba A; Kusuki I; Kitawaki J
Int J Gynaecol Obstet; 2016 Nov; 135(2):135-139. PubMed ID: 27477035
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
13. Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study.
Yu Q; Zhang S; Li H; Wang P; Zvolanek M; Ren X; Dong L; Lang J
J Womens Health (Larchmt); 2019 Feb; 28(2):170-177. PubMed ID: 30461337
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study.
Parke S; Gude K; Roth K; Messina F
BMC Womens Health; 2024 Jun; 24(1):353. PubMed ID: 38890641
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial.
El Taha L; Abu Musa A; Khalifeh D; Khalil A; Abbasi S; Nassif J
Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():205-212. PubMed ID: 34826668
[TBL] [Abstract][Full Text] [Related]
17. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Osuga Y; Seki Y; Tanimoto M; Kusumoto T; Kudou K; Terakawa N
Fertil Steril; 2021 Feb; 115(2):397-405. PubMed ID: 32912633
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice.
Techatraisak K; Hestiantoro A; Ruey S; Banal-Silao MJ; Kim MR; Seong SJ; Thaufik S; Ahlers C; Shin SY; Lee BS
BMC Womens Health; 2019 May; 19(1):68. PubMed ID: 31096979
[TBL] [Abstract][Full Text] [Related]
19. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
